{"gene":"IRF2","run_date":"2026-04-28T18:06:54","timeline":{"discoveries":[{"year":1989,"finding":"IRF-2 was identified as a transcription factor that binds to the same regulatory cis-elements as IRF-1 within IFN and IFN-inducible gene promoters, but functions as a transcriptional repressor rather than an activator, suppressing IRF-1 function by competing for the same binding sequences.","method":"cDNA cloning, DNA binding assays, transcriptional reporter assays, competition experiments","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 — original discovery paper with multiple orthogonal methods, foundational work replicated across hundreds of subsequent studies","pmids":["2475256"],"is_preprint":false},{"year":1993,"finding":"The DNA recognition sequences of IRF-1 and IRF-2 are virtually indistinguishable; both factors bind the same consensus sequences within IFN and IFN-inducible gene promoters with similar affinities, as determined by PCR-assisted DNA-binding site selection.","method":"PCR-assisted DNA binding site selection, EMSA","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 — biochemical determination of DNA recognition sequences with rigorous controls","pmids":["7687740"],"is_preprint":false},{"year":1993,"finding":"Targeted disruption of IRF-2 in mice results in up-regulated type I IFN induction following NDV infection, demonstrating that IRF-2 functions as a negative regulator of IFN gene transcription in vivo. IRF-2 knockout mice also exhibit bone marrow suppression of hematopoiesis and B lymphopoiesis.","method":"Gene targeting in embryonic stem cells, knockout mice, viral infection assays","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 — clean KO with defined cellular and molecular phenotype, replicated across labs","pmids":["8402903"],"is_preprint":false},{"year":1994,"finding":"IRF-2 possesses a transcriptional repression domain in its carboxyl-terminal region and a latent activation domain in its central region. Repression by IRF-2 involves both competition with IRF-1 for promoter binding and silencing of nearby activators via a LexA fusion approach.","method":"Deletion mapping, LexA fusion transcriptional assays, reporter gene assays","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1 — domain mapping with mutagenesis and functional validation","pmids":["8152803"],"is_preprint":false},{"year":1994,"finding":"The human IRF-2 gene is located at chromosome 4q35.1. The IRF-2 promoter contains an IRF binding site, and IRF-2 gene expression is regulated by IRF-1, establishing a gene network for autoregulation of the IFN system.","method":"FISH chromosomal mapping, promoter analysis, transient and stable transfection","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 2 — direct experimental mapping and promoter functional validation","pmids":["7507207"],"is_preprint":false},{"year":1995,"finding":"IRF-2 (identified as histone nuclear factor M, HiNF-M) was purified and shown to be a 48 kDa protein that binds the cell cycle element (CCE) in the human histone H4 gene promoter and activates its transcription, linking IRF-2 to cell cycle-regulated gene expression at the G1/S transition.","method":"Protein purification, EMSA, transcriptional reporter assays, recombinant protein binding","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 — protein purification, identity confirmation, and functional transcriptional assay","pmids":["7566094"],"is_preprint":false},{"year":1995,"finding":"The oncogenic activity of IRF-2 maps to its N-terminal DNA binding/transcriptional repression domain (first 160 amino acids). Overexpression of wild-type or truncated IRF-2 transforms NIH3T3 cells in vitro and promotes tumor formation in vivo.","method":"C-terminal deletion mutagenesis, NIH3T3 transformation assay, soft agar colony assay, nude mouse tumor formation","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1 — systematic domain mutagenesis with multiple functional readouts in vitro and in vivo","pmids":["7630638"],"is_preprint":false},{"year":1997,"finding":"IRF-2 is phosphorylated in vivo on serine residues. In vitro, recombinant IRF-2 is a substrate for PKA, PKC, and CK2, but not for JNK1, p38, or ERK2, indicating selective kinase regulation of IRF-2.","method":"In vivo 32P labeling with immunoprecipitation, in vitro kinase assays, 2D phosphopeptide mapping, phosphoamino acid analysis","journal":"Journal of cellular biochemistry","confidence":"High","confidence_rationale":"Tier 1 — in vitro kinase assay combined with in vivo phosphorylation validation","pmids":["9213219"],"is_preprint":false},{"year":1998,"finding":"Cell cycle regulation of histone H4 gene transcription requires IRF-2. IRF-2-null embryonic fibroblasts lose stringent cell cycle control of histone H4 expression, and reintroduction of IRF-2 restores both mRNA levels and cell cycle-regulated transcription.","method":"IRF-2 knockout fibroblasts, synchronized cell culture, mRNA analysis, complementation with IRF-2 re-expression","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — clean KO with functional rescue experiment and defined molecular phenotype","pmids":["9417064"],"is_preprint":false},{"year":1998,"finding":"The solution structure of the IRF-2 DNA-binding domain (DBD) was determined by NMR spectroscopy. The DBD adopts a winged helix-turn-helix (wHTH) fold with a four-stranded antiparallel beta sheet and three alpha helices. A long loop (Pro37-Asp51) and the second helix of the HTH motif participate in DNA recognition.","method":"NMR spectroscopy, DNA binding experiments","journal":"Structure","confidence":"High","confidence_rationale":"Tier 1 — NMR structure determination with DNA binding validation","pmids":["9562558"],"is_preprint":false},{"year":1999,"finding":"IRF-2 acts as a transcriptional repressor of the 2-5A synthetase and p21 gene promoters by direct binding to promoter IRF elements, counterbalancing IRF-1 activation. IRF-1 also induces IRF-2 expression via an IRF-E element in the IRF-2 promoter, establishing an autoinhibitory feedback loop.","method":"Ectopic expression, EMSA, cotransfection reporter assays, antisense approach","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 — direct binding and transcriptional reporter assays with functional consequence","pmids":["10321737"],"is_preprint":false},{"year":2000,"finding":"IRF-2 negatively regulates IFN-alpha/beta-induced gene transcription; CD8+ T cell abnormalities and inflammatory skin disease in IRF-2-deficient mice are suppressed by nullizygosity for genes that positively regulate IFN-alpha/beta signaling, placing IRF-2 as a negative regulator of IFN-alpha/beta signaling in vivo.","method":"IRF-2 KO mice, genetic epistasis (double KO with IFN-alpha/beta pathway genes), in vitro T cell assays","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis in vivo with defined pathway placement and cellular phenotype","pmids":["11114377"],"is_preprint":false},{"year":2000,"finding":"IRF-2 deficiency in macrophages results in increased basal and IFN-gamma-inducible COX-2 mRNA and protein expression, and two IFN stimulation response elements in the COX-2 promoter bind endogenous IRF-2 to repress transcription.","method":"IRF-2 KO macrophages, reporter gene assays, EMSA with endogenous protein, COX-2 protein and PGE2 measurement","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 — KO macrophages with defined molecular and biochemical phenotype, confirmed by direct promoter binding","pmids":["10859338"],"is_preprint":false},{"year":2002,"finding":"IFN-gamma-induced IRF-1 and IRF-2 bind to three distinct sites in the IL-4 promoter and function as transcriptional repressors, providing a direct mechanism by which IFN-gamma suppresses Th2 cytokine IL-4 expression.","method":"Promoter reporter assays, EMSA, chromatin-IP-like binding studies, CD4+ T cell assays","journal":"Immunity","confidence":"Medium","confidence_rationale":"Tier 2 — direct promoter binding and functional repression demonstrated in relevant cell type","pmids":["12479817"],"is_preprint":false},{"year":2003,"finding":"IRF-2 co-occupies the IRF-E of the CIITA type IV promoter with IRF-1, stabilizing IRF-1 binding and cooperating to activate CIITA transcription. The IRF-2 DNA binding domain is sufficient for cooperative activation with IRF-1, while a latent activation domain in IRF-2 is required for IRF-2 transactivation of this promoter.","method":"EMSA, off-rate experiments, deletion analysis, cotransfection reporter assays","journal":"Molecular immunology","confidence":"Medium","confidence_rationale":"Tier 2 — domain mapping with direct DNA binding and functional reporter assays","pmids":["12493643"],"is_preprint":false},{"year":2004,"finding":"Blimp-1, IRF-1, and IRF-2 share similar binding affinities for regulatory sites containing the GAAAG sequence and can compete for the same binding sites in vitro and in vivo, including the IFN-beta promoter, as shown by chromatin immunoprecipitation.","method":"Binding competition assays, equilibrium dissociation constant measurement, chromatin immunoprecipitation, cotransfection assays","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1-2 — ChIP in vivo plus quantitative in vitro binding characterization","pmids":["15494505"],"is_preprint":false},{"year":2008,"finding":"IRF-2 regulates NF-kappaB activity by physically interacting with RelA/p65 and promoting its nuclear localization. The N-terminal domain of IRF-2 is required for this interaction; knockdown of IRF-2 attenuates TNFalpha-induced NF-kappaB transcription by inhibiting RelA nuclear translocation.","method":"Co-immunoprecipitation, subcellular localization assays, siRNA knockdown, NF-kappaB reporter assays, dominant-negative deletion","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2-3 — physical interaction and functional consequence demonstrated, single lab","pmids":["18395009"],"is_preprint":false},{"year":2008,"finding":"IRF2 is sumoylated in vivo through interaction with the SUMO-E3 ligase PIASy at three sumoylation sites. Sumoylation of IRF2 does not affect nuclear localization or DNA binding but increases its ability to inhibit IRF1 transcriptional activity and decreases its ability to activate ISRE- and H4-driven promoters.","method":"Co-IP with PIASy, in vivo sumoylation assay, mutagenesis of sumoylation sites, reporter gene assays, subcellular localization, DNA binding assays","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 — identification of writer (PIASy), sites mapped by mutagenesis, functional consequences measured","pmids":["18514056"],"is_preprint":false},{"year":2008,"finding":"IRF2 is a substrate of Mdm2 E3-ubiquitin ligase. Mdm2-mediated ubiquitination of IRF2 requires interaction at both the hydrophobic pocket and the acid domain of Mdm2, mirroring the dual-site mechanism used for p53. IRF2-Mdm2 complex formation occurs in cells.","method":"Bioinformatics, in vitro ubiquitination assay, mutagenesis of Mdm2-binding sites on IRF2, co-immunoprecipitation in cells","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 1 — reconstituted in vitro ubiquitination assay with mutagenesis validation and in-cell co-IP","pmids":["19032150"],"is_preprint":false},{"year":2008,"finding":"IRF2 maintains normal erythropoiesis by attenuating type I IFN signaling. Additional homozygous deletion of IFNAR1 in Irf2-deficient mice rescues the erythropoiesis defect, establishing IRF2 as a regulator of homeostatic erythropoiesis through negative regulation of type I IFN signaling in erythroid cells.","method":"IRF-2 KO mice, double KO epistasis (Irf2-/-; Ifnar1-/-), flow cytometry of erythroid progenitors, Bcl-XL expression analysis","journal":"Experimental hematology","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis places IRF2 in the IFN-alpha/beta pathway for erythropoiesis regulation","pmids":["18207304"],"is_preprint":false},{"year":2008,"finding":"IRF2-binding protein-1 (IRF2-BP1), a transcriptional corepressor of IRF2 containing a RING-finger domain, acts as an E3 ubiquitin ligase for JDP2 and represses ATF2-mediated transcription from CRE-containing promoters.","method":"Epitope-tag pulldown to identify IRF2-BP1 as JDP2-binding protein, ubiquitination assay, reporter gene assays","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 2 — biochemical identification of interaction and E3 ligase activity, single lab","pmids":["18671972"],"is_preprint":false},{"year":2011,"finding":"IRF2 directly binds to an interferon-stimulated response element (ISRE) in the MHV68 M2 gene promoter during latency in vivo and functions as an IFNalphabeta-induced transcriptional repressor of M2, limiting viral reactivation from latency. Virus lacking the M2 ISRE shows IRF2-dependent dysregulated M2 expression and uncontrolled reactivation.","method":"ChIP in vivo, ISRE mutant virus (ISREΔ), IRF2 knockout mice, viral load and reactivation assays","journal":"PLoS pathogens","confidence":"High","confidence_rationale":"Tier 2 — ChIP in vivo, genetic validation with IRF2 KO and ISRE mutant virus","pmids":["22114555"],"is_preprint":false},{"year":2015,"finding":"IRF2 (not IRF1) is constitutively associated with the TLR3 promoter in unstimulated cells and maintains an open chromatin structure with active histone marks (H3K9/K14 acetylation, H3K4 tri-methylation), while IRF1 binding is induced upon IFN stimulation to drive transcriptional activation. Both IRF1 and IRF2 interact with the BAF chromatin remodeling complex.","method":"ChIP assays, histone modification analysis, BAF complex interaction assays, IRF1/IRF2 KO cells, gene expression analysis","journal":"Cell & bioscience","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP and BAF interaction with KO validation, single lab","pmids":["25960866"],"is_preprint":false},{"year":2017,"finding":"IRF2 regulates basal expression of FAM111A; depletion of IRF2 reduces FAM111A expression, and this is the mechanism by which IRF2 knockdown enhances replication of an SPI-1 deletion orthopoxvirus mutant in human cells. Microarray analysis, qRT-PCR, and immunoblotting confirmed IRF2 as a transcriptional regulator of FAM111A.","method":"Genome-wide siRNA screen, secondary screen confirmation, microarray analysis, qRT-PCR, immunoblotting","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 — functional genomic screen with orthogonal validation of IRF2-FAM111A regulatory relationship","pmids":["28320935"],"is_preprint":false},{"year":2019,"finding":"IRF2 directly binds to a unique site within the GSDMD promoter to drive GSDMD transcription. Loss of IRF2 substantially attenuates GSDMD expression in macrophages and multiple tissues, reducing IL-1beta secretion and inhibiting pyroptosis by both canonical and non-canonical inflammasomes. Disruption of the single IRF2-binding site in the GSDMD promoter abolishes inflammasome signaling.","method":"ENU forward genetic screen, IRF2 KO macrophages and tissues, ChIP/promoter binding, site-directed mutagenesis of GSDMD promoter, pyroptosis and IL-1beta secretion assays","journal":"Science signaling","confidence":"High","confidence_rationale":"Tier 1-2 — forward genetic screen + direct promoter binding + mutagenesis + KO phenotype with multiple orthogonal validations","pmids":["31113851"],"is_preprint":false},{"year":2019,"finding":"A genome-wide CRISPR screen identified IRF2 as essential for caspase-4 expression in human monocytes, establishing IRF2 as a transcriptional activator of CASP4 and thereby a regulator of non-canonical inflammasome-driven pyroptosis following cytosolic LPS delivery. IFN-gamma priming can induce IRF1 to compensate for IRF2 deficiency.","method":"Genome-wide CRISPR/Cas9 screen, IRF2 KO human monocytes and iPSC-derived monocytes, caspase-4 expression analysis, pyroptosis assays, bacterial infection","journal":"EMBO reports","confidence":"High","confidence_rationale":"Tier 2 — genome-wide unbiased screen, KO validation in primary and iPSC-derived cells, functional pyroptosis readout","pmids":["31353801"],"is_preprint":false},{"year":2019,"finding":"IRF2 identified in a CRISPR-based forward genetic screen as a transcriptional activator of multiple MHC-I pathway components (immunoproteasomes, TAP, ERAP1) and a transcriptional repressor of PD-L1. Loss of IRF2 impairs cytosol-to-ER peptide transport and N-terminal peptide trimming, reducing antigen presentation.","method":"CRISPR forward genetic screen in HeLa cells, IRF2 KO, antigen presentation assays, PD-L1 expression measurement","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — unbiased CRISPR screen with functional KO validation and defined mechanistic pathway","pmids":["31471524"],"is_preprint":false},{"year":2019,"finding":"KRAS* (oncogenic KRAS) represses IRF2 expression, and IRF2 in turn directly represses CXCL3 expression. KRAS*-mediated loss of IRF2 leads to elevated CXCL3, which promotes MDSC migration to the tumor microenvironment via CXCR2, mediating immune suppression and anti-PD-1 resistance.","method":"Enforced IRF2 expression in CRC models, CXCL3 reporter assays, CXCR2 inhibition, anti-PD-1 treatment experiments","journal":"Cancer cell","confidence":"High","confidence_rationale":"Tier 2 — pathway epistasis established by gain-of-function rescue and pharmacological inhibition with defined molecular cascade","pmids":["30905761"],"is_preprint":false},{"year":2020,"finding":"IRF-2 overexpression down-regulates IFN-gamma-induced PD-L1 promoter activity and protein levels in hepatocellular carcinoma cells. Two IRF-1 response elements (IRE1 and IRE2) in the PD-L1 (CD274) promoter were identified, and site-directed mutagenesis confirmed both are functional. IRF-2 antagonizes IRF-1 for binding to the IRE promoter element in PD-L1.","method":"IRF-2 overexpression, PD-L1 promoter reporter assays, site-directed mutagenesis, protein expression analysis","journal":"Cancer immunology, immunotherapy","confidence":"Medium","confidence_rationale":"Tier 2 — promoter mutagenesis with functional reporter validation, single lab","pmids":["32377817"],"is_preprint":false},{"year":2020,"finding":"IRF2 maintains stemness of colonic stem cells by limiting IFN signaling. Conditional intestinal epithelial deletion of Irf2 (Irf2ΔIEC mice) reduces colonic stem cell numbers and organoid-forming potential, with premature differentiation into transit-amplifying cells, and impairs colon epithelium regeneration after colitis.","method":"Conditional KO mice (Irf2ΔIEC), organoid assay, flow cytometry, poly(I:C) injection model, DSS colitis model","journal":"Scientific reports","confidence":"High","confidence_rationale":"Tier 2 — tissue-specific conditional KO with multiple functional readouts and mechanistic link to IFN signaling","pmids":["32901054"],"is_preprint":false},{"year":2021,"finding":"IRF2 directly binds to the GSDMD promoter (confirmed by ChIP and dual-luciferase reporter assay) to drive GSDMD transcription and promote pyroptosis in cardiomyocytes during myocardial infarction. IRF2 expression in this context may be regulated by HIF-1 signaling.","method":"ChIP, dual-luciferase reporter assay, IRF2 silencing in hypoxia model, MI mouse model","journal":"Molecular medicine reports","confidence":"Medium","confidence_rationale":"Tier 2 — direct promoter binding confirmed by ChIP and mutagenesis, functional KD phenotype","pmids":["34878155"],"is_preprint":false},{"year":2021,"finding":"IRF2 transcriptionally activates CENP-N expression by binding its promoter (confirmed by ChIP and dual luciferase reporter assays). CENP-N in turn forms a complex with AKT (confirmed by co-IP and GST pulldown) to regulate glucose metabolism, proliferation, and apoptosis in nasopharyngeal carcinoma cells.","method":"ChIP, dual luciferase reporter assay, co-IP, GST pulldown, siRNA knockdown, overexpression","journal":"Journal of experimental & clinical cancer research","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP and co-IP with functional validation, single lab","pmids":["34893086"],"is_preprint":false},{"year":2022,"finding":"IRF2 expression in CD8+ T cells is driven by sustained IFN signaling within tumors. CD8+ T cell-specific deletion of IRF2 prevents acquisition of the T cell exhaustion transcriptional program and instead enables sustained effector functions, promoting long-term tumor control. The tumor control by IRF2-deficient CD8+ T cells requires integration of both type I and type II IFN signals.","method":"CD8+ T cell-specific IRF2 KO, adoptive transfer, tumor models, transcriptional profiling, checkpoint blockade and adoptive cell therapy experiments","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 — cell type-specific KO with defined transcriptional program and functional tumor control phenotype","pmids":["36370712"],"is_preprint":false},{"year":2017,"finding":"HCFC2 promotes the binding of IRF2 (and IRF1) to the Tlr3 promoter; without HCFC2, IRF2 cannot effectively bind the Tlr3 promoter, and a large subset of IRF2-dependent interferon-regulated genes fails to be transcribed properly. HCFC2 mutations were identified by ENU mutagenesis and confirmed to compromise poly(I:C) responses and viral survival.","method":"ENU mutagenesis screen, ChIP for IRF1/IRF2 binding at Tlr3 promoter, macrophage functional assays, viral survival assays","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 — in vivo ENU screen with ChIP validation establishing HCFC2 as a cofactor for IRF2 promoter binding","pmids":["28970238"],"is_preprint":false},{"year":2023,"finding":"IRF2 is required cell-intrinsically for the development of Ly6Clo nonclassical monocytes. DLL1-induced NOTCH2 signaling can drive Ly6Chi to Ly6Clo monocyte transition in vitro, and this transition requires IRF2 but can occur in the absence of NUR77 or BCL6, placing IRF2 downstream of NOTCH2 in a transcriptional hierarchy for nonclassical monocyte development.","method":"IRF2 KO mice, myeloid progenitor-specific deletions, in vitro DLL1-induced transition assay, flow cytometry","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 — genetic epistasis with cell-intrinsic KO and defined developmental phenotype","pmids":["37607223"],"is_preprint":false}],"current_model":"IRF2 is a winged helix-turn-helix transcription factor that binds the same regulatory elements as the activator IRF1, primarily functioning as a transcriptional repressor of IFN-stimulated genes by competing for promoter occupancy and recruiting repressive activity through its C-terminal domain; however, it also acts as a transcriptional activator of specific targets including histone H4, GSDMD, CASP4, and MHC-I pathway genes, and its activity is modulated post-translationally by phosphorylation (via PKA, PKC, CK2), SUMOylation (via PIASy), and ubiquitination (via Mdm2), while in vivo it is essential for attenuating type I IFN signaling to maintain erythropoiesis, colonic stem cell homeostasis, and normal immune cell development (NK cells, nonclassical monocytes, B cells), and drives CD8+ T cell exhaustion in tumors through sustained IFN feedback."},"narrative":{"teleology":[{"year":1989,"claim":"The discovery that IRF2 binds the same IFN regulatory elements as IRF1 yet functions as a repressor established the paradigm of antagonistic IRF pairing in IFN gene regulation.","evidence":"cDNA cloning with DNA binding and transcriptional reporter competition assays in Cell","pmids":["2475256"],"confidence":"High","gaps":["Repression mechanism not resolved — competitive displacement vs. active silencing unclear","No in vivo validation at this stage"]},{"year":1993,"claim":"Demonstration that IRF1 and IRF2 recognize virtually identical DNA sequences, combined with the phenotype of IRF2 knockout mice showing exaggerated IFN induction and impaired hematopoiesis, proved that IRF2 is a physiological brake on IFN signaling and hematopoietic homeostasis in vivo.","evidence":"PCR-assisted binding site selection (EMSA) and targeted gene disruption in mice","pmids":["7687740","8402903"],"confidence":"High","gaps":["Cell-type-specific contributions of IRF2 not resolved","Mechanism linking IFN derepression to bone marrow suppression unknown"]},{"year":1994,"claim":"Mapping of a C-terminal repression domain and a latent central activation domain within IRF2 resolved how a single factor can act as both repressor and context-dependent activator.","evidence":"Deletion mapping and LexA fusion transcriptional assays","pmids":["8152803"],"confidence":"High","gaps":["Corepressor/coactivator identity unknown","Whether both domains function simultaneously or are context-switched not determined"]},{"year":1995,"claim":"Identification of IRF2 as the long-sought histone H4 activator HiNF-M revealed that IRF2 has bona fide transcriptional activator function at a cell cycle–regulated promoter, fundamentally expanding its role beyond IFN repression.","evidence":"Protein purification from HeLa nuclei, identity confirmation, EMSA, and transcriptional reporter assays","pmids":["7566094"],"confidence":"High","gaps":["Cell cycle–dependent regulation of IRF2 activity not mechanistically explained","Chromatin context of activation not addressed"]},{"year":1997,"claim":"Demonstration that IRF2 is phosphorylated in vivo and selectively targeted by PKA, PKC, and CK2 in vitro established post-translational modification as a regulatory layer for IRF2 activity.","evidence":"In vivo 32P labeling, immunoprecipitation, in vitro kinase assays, 2D phosphopeptide mapping","pmids":["9213219"],"confidence":"High","gaps":["Functional consequence of specific phosphorylation events on DNA binding or transcription not determined","In vivo kinase-IRF2 relationships not validated genetically"]},{"year":1998,"claim":"NMR determination of the IRF2 DNA-binding domain structure revealed a winged helix-turn-helix fold and identified specific residues mediating DNA recognition, providing the first atomic-resolution understanding of IRF-DNA interaction.","evidence":"NMR spectroscopy of the IRF2 DBD","pmids":["9562558"],"confidence":"High","gaps":["Full-length IRF2 structure not solved","Co-crystal with DNA not obtained at this point"]},{"year":1998,"claim":"Rescue of histone H4 cell cycle regulation by IRF2 re-expression in knockout fibroblasts demonstrated that IRF2 is required, not merely sufficient, for coupling H4 transcription to S-phase entry.","evidence":"IRF2 KO fibroblasts synchronized in culture with complementation rescue","pmids":["9417064"],"confidence":"High","gaps":["Direct mechanism linking IRF2 to cell cycle machinery not identified","Whether IRF2 senses cell cycle signals directly or via upstream regulation unknown"]},{"year":2000,"claim":"Genetic epistasis showing that CD8+ T cell and skin disease phenotypes of IRF2 KO mice are rescued by loss of IFN-α/β pathway genes firmly placed IRF2 as a negative regulator of type I IFN signaling in vivo, and loss of IRF2 in macrophages derepressed COX-2 through direct promoter binding, expanding the target repertoire.","evidence":"Double-KO genetic epistasis in mice; ChIP and EMSA on COX-2 promoter in KO macrophages","pmids":["11114377","10859338"],"confidence":"High","gaps":["Whether IRF2 regulates type I IFN signaling transcriptionally or post-transcriptionally not fully dissected","COX-2 regulation not tested in non-macrophage lineages"]},{"year":2008,"claim":"Identification of SUMOylation by PIASy (enhancing repressor function) and ubiquitination by Mdm2, together with the physical interaction with RelA/p65 promoting NF-κB nuclear translocation, revealed a multi-layered post-translational regulatory network controlling IRF2 activity and expanded its role beyond classical IRF-E targets.","evidence":"In vivo SUMOylation assays with site mutagenesis; reconstituted in vitro Mdm2-dependent ubiquitination; co-IP of IRF2-RelA and NF-κB reporter assays with siRNA knockdown","pmids":["18514056","19032150","18395009"],"confidence":"Medium","gaps":["Physiological triggers for SUMOylation and ubiquitination unknown","RelA interaction not validated by reciprocal endogenous co-IP in multiple cell types","Functional interplay between SUMOylation and ubiquitination not tested"]},{"year":2008,"claim":"Genetic epistasis (Irf2−/−;Ifnar1−/− double KO) rescuing the erythropoiesis defect of IRF2 KO mice established that IRF2 maintains homeostatic erythropoiesis specifically by attenuating type I IFN receptor signaling in erythroid progenitors.","evidence":"Double-KO mice with flow cytometric analysis of erythroid progenitors and Bcl-XL measurement","pmids":["18207304"],"confidence":"High","gaps":["Direct IRF2 target genes in erythroid progenitors not identified","Whether IRF2 acts cell-autonomously in erythroid cells not formally proven with conditional KO"]},{"year":2015,"claim":"ChIP studies showing constitutive IRF2 occupancy at the TLR3 promoter maintaining open chromatin with active histone marks, and interaction with the BAF remodeling complex, revealed a chromatin-architectural role for IRF2 at baseline that primes gene expression prior to IFN stimulation.","evidence":"ChIP for IRF2 and histone marks, BAF complex interaction assays, IRF1/IRF2 KO cell expression analysis","pmids":["25960866"],"confidence":"Medium","gaps":["BAF subunit specificity for IRF2 interaction not determined","Genome-wide extent of this chromatin-priming role unknown"]},{"year":2017,"claim":"HCFC2 was identified as a cofactor required for IRF2 binding to the Tlr3 promoter and a large subset of IRF2-dependent IFN-regulated genes, revealing that IRF2 promoter occupancy is not solely determined by its intrinsic DNA-binding properties but requires accessory factors.","evidence":"ENU mutagenesis screen in mice, ChIP for IRF2 at Tlr3 promoter with and without HCFC2, macrophage poly(I:C) response and viral survival assays","pmids":["28320935","28970238"],"confidence":"High","gaps":["Structural basis of HCFC2-IRF2 interaction not resolved","Whether HCFC2 dependency is universal for all IRF2 targets unknown"]},{"year":2019,"claim":"Convergent forward genetic and CRISPR screens established IRF2 as a direct transcriptional activator of GSDMD and CASP4, two essential executors of pyroptosis, and of MHC-I pathway components (immunoproteasomes, TAP, ERAP1), while simultaneously repressing PD-L1 and CXCL3, placing IRF2 at a regulatory nexus of innate immunity, antigen presentation, and tumor immune evasion.","evidence":"ENU screen and ChIP/mutagenesis for GSDMD; CRISPR screen in human monocytes for CASP4; CRISPR screen in HeLa for MHC-I pathway; KRAS-driven CRC models for CXCL3 axis","pmids":["31113851","31353801","31471524","30905761"],"confidence":"High","gaps":["Whether GSDMD and CASP4 activation uses the latent activation domain or a distinct mechanism not resolved","Direct binding to CASP4 promoter not confirmed by ChIP","Quantitative contribution of IRF2 loss to immune evasion in patients not established"]},{"year":2020,"claim":"Tissue-specific conditional deletion showed that IRF2 maintains colonic stem cell self-renewal by limiting IFN signaling, with its loss causing premature differentiation and impaired epithelial regeneration after colitis, extending IRF2's IFN-attenuating role to epithelial homeostasis.","evidence":"Irf2ΔIEC conditional KO mice with organoid assays, flow cytometry, poly(I:C) and DSS colitis models","pmids":["32901054"],"confidence":"High","gaps":["Direct IRF2 target genes in colonic stem cells not identified","Whether type I vs. type III IFN is the dominant signal restrained by IRF2 in gut epithelium not distinguished"]},{"year":2022,"claim":"Cell-type-specific deletion of IRF2 in CD8+ T cells prevented acquisition of the exhaustion transcriptional program in tumors and sustained effector function, establishing that IFN-driven IRF2 expression is a critical checkpoint linking chronic IFN signaling to T cell dysfunction.","evidence":"CD8+ T cell-specific IRF2 conditional KO, adoptive transfer into tumor-bearing mice, transcriptional profiling, checkpoint blockade experiments","pmids":["36370712"],"confidence":"High","gaps":["Direct transcriptional targets of IRF2 that execute the exhaustion program in CD8+ T cells not catalogued","Whether IRF2 acts alone or requires co-factors (e.g. TOX, NFAT) for exhaustion programming unknown"]},{"year":2023,"claim":"Placement of IRF2 downstream of NOTCH2 signaling in the Ly6Chi-to-Ly6Clo nonclassical monocyte transition resolved the signaling hierarchy controlling this differentiation step and established IRF2 as the required transcription factor independently of NUR77 and BCL6.","evidence":"IRF2 KO mice, myeloid progenitor-specific deletions, in vitro DLL1-induced transition assay with flow cytometry","pmids":["37607223"],"confidence":"Medium","gaps":["Direct IRF2 target genes that execute the nonclassical monocyte program not identified","Whether NOTCH2 directly induces IRF2 expression or acts through intermediaries not resolved"]},{"year":null,"claim":"Major open questions include the identity of the full genome-wide IRF2 target repertoire in specific cell types, the structural basis for context-dependent switching between repressor and activator modes, the interplay among phosphorylation/SUMOylation/ubiquitination in regulating IRF2 function in vivo, and the therapeutic potential of modulating IRF2 to reverse CD8+ T cell exhaustion in cancer immunotherapy.","evidence":"","pmids":[],"confidence":"Low","gaps":["No full-length IRF2 structure in complex with corepressors or coactivators","In vivo phosphosite-specific mutant phenotypes not characterized","Pharmacological tools to modulate IRF2 activity do not exist"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[0,1,5,9,15,24]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,3,5,8,10,14,24,25,26]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[3,9,17]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,3,5,8,10,14,24,25,26]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[2,11,19,25,26,32]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[5,8]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[24,25,30]}],"complexes":[],"partners":["IRF1","PIASY","MDM2","RELA","HCFC2","BLIMP1"],"other_free_text":[]},"mechanistic_narrative":"IRF2 is a winged helix-turn-helix transcription factor that functions as both a transcriptional repressor and activator, serving as a central modulator of interferon signaling, innate immune gene expression, cell cycle control, and immune cell differentiation. IRF2 binds the same ISRE/IRF-E consensus elements as the activator IRF1 with virtually indistinguishable affinity and represses IFN-stimulated genes by competitive promoter occupancy and through a C-terminal repression domain, while a latent activation domain enables it to directly activate transcription of histone H4, GSDMD, CASP4, CIITA, and MHC-I pathway genes [PMID:2475256, PMID:7687740, PMID:8152803, PMID:7566094, PMID:31113851, PMID:31471524]. Its activity is modulated by phosphorylation (PKA, PKC, CK2), SUMOylation via PIASy that enhances repressor function, and Mdm2-mediated ubiquitination [PMID:9213219, PMID:18514056, PMID:19032150]. In vivo, IRF2 is essential for attenuating type I IFN signaling to maintain homeostatic erythropoiesis, colonic stem cell renewal, B lymphopoiesis, nonclassical monocyte development, and NK/CD8+ T cell homeostasis; within tumors, sustained IFN-driven IRF2 expression in CD8+ T cells promotes the exhaustion transcriptional program, and its deletion restores effector function and long-term tumor control [PMID:8402903, PMID:11114377, PMID:18207304, PMID:32901054, PMID:37607223, PMID:36370712]."},"prefetch_data":{"uniprot":{"accession":"P14316","full_name":"Interferon regulatory factor 2","aliases":[],"length_aa":349,"mass_kda":39.4,"function":"DNA-binding transcription factor that specifically binds to the upstream regulatory region of type I interferon (IFN) and IFN-inducible genes and regulates their expression (PubMed:39013473, PubMed:7687740). Mainly acts as a transcription repressor, repressing expression (PubMed:39013473). Also acts as an activator for several genes including H4 and IL7 (PubMed:15226432, PubMed:9540062). Constitutively binds to the ISRE promoter to activate IL7 (PubMed:15226432). Involved in cell cycle regulation through binding the site II (HiNF-M) promoter region of H4 and activating transcription during cell growth (PubMed:9540062). Antagonizes IRF1 transcriptional activation (By similarity) Unable to bind to IRF2BP1 and IRF2BP2 corepressors and cannot mediate repression","subcellular_location":"Nucleus; Chromosome","url":"https://www.uniprot.org/uniprotkb/P14316/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/IRF2","classification":"Not Classified","n_dependent_lines":56,"n_total_lines":1208,"dependency_fraction":0.046357615894039736},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/IRF2","total_profiled":1310},"omim":[{"mim_id":"621243","title":"TRANSCRIPTION ACTIVATION SUPPRESSOR FAMILY, MEMBER 2; TASOR2","url":"https://www.omim.org/entry/621243"},{"mim_id":"615332","title":"INTERFERON REGULATORY FACTOR 2-BINDING PROTEIN 2; IRF2BP2","url":"https://www.omim.org/entry/615332"},{"mim_id":"615331","title":"INTERFERON REGULATORY FACTOR 2-BINDING PROTEIN 1; IRF2BP1","url":"https://www.omim.org/entry/615331"},{"mim_id":"608657","title":"JUN DIMERIZATION PROTEIN 2; JDP2","url":"https://www.omim.org/entry/608657"},{"mim_id":"605402","title":"CD274 MOLECULE; CD274","url":"https://www.omim.org/entry/605402"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Nucleoplasm","reliability":"Enhanced"},{"location":"Cell Junctions","reliability":"Additional"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/IRF2"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"P14316","domains":[{"cath_id":"1.10.10.10","chopping":"7-110","consensus_level":"high","plddt":94.1486,"start":7,"end":110}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P14316","model_url":"https://alphafold.ebi.ac.uk/files/AF-P14316-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P14316-F1-predicted_aligned_error_v6.png","plddt_mean":63.94},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=IRF2","jax_strain_url":"https://www.jax.org/strain/search?query=IRF2"},"sequence":{"accession":"P14316","fasta_url":"https://rest.uniprot.org/uniprotkb/P14316.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P14316/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P14316"}},"corpus_meta":[{"pmid":"2475256","id":"PMC_2475256","title":"Structurally similar but functionally distinct factors, IRF-1 and IRF-2, bind to the same regulatory elements of IFN and IFN-inducible genes.","date":"1989","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/2475256","citation_count":901,"is_preprint":false},{"pmid":"8402903","id":"PMC_8402903","title":"Targeted disruption of IRF-1 or IRF-2 results in abnormal type I IFN gene induction and aberrant lymphocyte development.","date":"1993","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/8402903","citation_count":584,"is_preprint":false},{"pmid":"30905761","id":"PMC_30905761","title":"KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer.","date":"2019","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/30905761","citation_count":507,"is_preprint":false},{"pmid":"7687740","id":"PMC_7687740","title":"Recognition DNA sequences of interferon regulatory factor 1 (IRF-1) and IRF-2, regulators of cell growth and the interferon system.","date":"1993","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/7687740","citation_count":404,"is_preprint":false},{"pmid":"2208287","id":"PMC_2208287","title":"Absence of the type I IFN system in EC cells: transcriptional activator (IRF-1) and repressor (IRF-2) genes are developmentally regulated.","date":"1990","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/2208287","citation_count":356,"is_preprint":false},{"pmid":"7507207","id":"PMC_7507207","title":"Structure and regulation of the human interferon regulatory factor 1 (IRF-1) and IRF-2 genes: implications for a gene network in the interferon system.","date":"1994","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/7507207","citation_count":271,"is_preprint":false},{"pmid":"11114377","id":"PMC_11114377","title":"CD8(+) T cell-mediated skin disease in mice lacking IRF-2, the transcriptional attenuator of interferon-alpha/beta signaling.","date":"2000","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/11114377","citation_count":207,"is_preprint":false},{"pmid":"7566094","id":"PMC_7566094","title":"Activation of a cell-cycle-regulated histone gene by the oncogenic transcription factor IRF-2.","date":"1995","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/7566094","citation_count":171,"is_preprint":false},{"pmid":"31113851","id":"PMC_31113851","title":"IRF2 transcriptionally induces GSDMD expression for pyroptosis.","date":"2019","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/31113851","citation_count":150,"is_preprint":false},{"pmid":"12479817","id":"PMC_12479817","title":"IFN-gamma represses IL-4 expression via IRF-1 and IRF-2.","date":"2002","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/12479817","citation_count":139,"is_preprint":false},{"pmid":"10934221","id":"PMC_10934221","title":"Deficiency in the transcription factor interferon regulatory factor (IRF)-2 leads to severely compromised development of natural killer and T helper type 1 cells.","date":"2000","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/10934221","citation_count":136,"is_preprint":false},{"pmid":"24607843","id":"PMC_24607843","title":"Survival in patients with high-risk prostate cancer is predicted by miR-221, which regulates proliferation, apoptosis, and invasion of prostate cancer cells by inhibiting IRF2 and SOCS3.","date":"2014","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/24607843","citation_count":107,"is_preprint":false},{"pmid":"10859338","id":"PMC_10859338","title":"Interferon regulatory factor (IRF)-1 and IRF-2 regulate interferon gamma-dependent cyclooxygenase 2 expression.","date":"2000","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/10859338","citation_count":107,"is_preprint":false},{"pmid":"28471447","id":"PMC_28471447","title":"MicroRNA-18a-5p functions as an oncogene by directly targeting IRF2 in lung cancer.","date":"2017","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/28471447","citation_count":104,"is_preprint":false},{"pmid":"15494505","id":"PMC_15494505","title":"B lymphocyte-induced maturation protein (Blimp)-1, IFN regulatory factor (IRF)-1, and IRF-2 can bind to the same regulatory sites.","date":"2004","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/15494505","citation_count":102,"is_preprint":false},{"pmid":"10415056","id":"PMC_10415056","title":"IL-12 is dysregulated in macrophages from IRF-1 and IRF-2 knockout mice.","date":"1999","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/10415056","citation_count":97,"is_preprint":false},{"pmid":"36370712","id":"PMC_36370712","title":"The transcription factor IRF2 drives interferon-mediated CD8+ T cell exhaustion to restrict anti-tumor immunity.","date":"2022","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/36370712","citation_count":93,"is_preprint":false},{"pmid":"8152803","id":"PMC_8152803","title":"The oncogenic transcription factor IRF-2 possesses a transcriptional repression and a latent activation domain.","date":"1994","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/8152803","citation_count":87,"is_preprint":false},{"pmid":"32377817","id":"PMC_32377817","title":"Interferon regulatory factor 1 (IRF-1) and IRF-2 regulate PD-L1 expression in hepatocellular carcinoma (HCC) cells.","date":"2020","source":"Cancer immunology, immunotherapy : CII","url":"https://pubmed.ncbi.nlm.nih.gov/32377817","citation_count":86,"is_preprint":false},{"pmid":"12543125","id":"PMC_12543125","title":"Cloning and expression analysis of rainbow trout Oncorhynchus mykiss interferon regulatory factor 1 and 2 (IRF-1 and IRF-2).","date":"2003","source":"Developmental and comparative immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12543125","citation_count":86,"is_preprint":false},{"pmid":"17363571","id":"PMC_17363571","title":"Involvement of IFN regulatory factor (IRF)-1 and IRF-2 in the formation and progression of human esophageal cancers.","date":"2007","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/17363571","citation_count":85,"is_preprint":false},{"pmid":"15914553","id":"PMC_15914553","title":"Negative control of basophil expansion by IRF-2 critical for the regulation of Th1/Th2 balance.","date":"2005","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/15914553","citation_count":85,"is_preprint":false},{"pmid":"31471524","id":"PMC_31471524","title":"Frequent Loss of IRF2 in Cancers Leads to Immune Evasion through Decreased MHC Class I Antigen Presentation and Increased PD-L1 Expression.","date":"2019","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/31471524","citation_count":78,"is_preprint":false},{"pmid":"31353801","id":"PMC_31353801","title":"A genome-wide screen identifies IRF2 as a key regulator of caspase-4 in human cells.","date":"2019","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/31353801","citation_count":77,"is_preprint":false},{"pmid":"9417064","id":"PMC_9417064","title":"Cell cycle regulation of histone H4 gene transcription requires the oncogenic factor IRF-2.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9417064","citation_count":77,"is_preprint":false},{"pmid":"9001242","id":"PMC_9001242","title":"Constitutive activation of Epstein-Barr virus (EBV) nuclear antigen 1 gene transcription by IRF1 and IRF2 during restricted EBV latency.","date":"1997","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/9001242","citation_count":65,"is_preprint":false},{"pmid":"7822029","id":"PMC_7822029","title":"Differential expression of interferon regulatory factor 1 (IRF-1), IRF-2, and interferon consensus sequence binding protein genes in lipopolysaccharide (LPS)-responsive and LPS-hyporesponsive macrophages.","date":"1995","source":"Infection and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/7822029","citation_count":65,"is_preprint":false},{"pmid":"31968218","id":"PMC_31968218","title":"Exosomes derived from human bone marrow mesenchymal stem cells transfer miR-222-3p to suppress acute myeloid leukemia cell proliferation by targeting IRF2/INPP4B.","date":"2020","source":"Molecular and cellular probes","url":"https://pubmed.ncbi.nlm.nih.gov/31968218","citation_count":63,"is_preprint":false},{"pmid":"10321737","id":"PMC_10321737","title":"Activation and repression of the 2-5A synthetase and p21 gene promoters by IRF-1 and IRF-2.","date":"1999","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/10321737","citation_count":59,"is_preprint":false},{"pmid":"34893086","id":"PMC_34893086","title":"The IRF2/CENP-N/AKT signaling axis promotes proliferation, cell cycling and apoptosis resistance in nasopharyngeal carcinoma cells by increasing aerobic glycolysis.","date":"2021","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/34893086","citation_count":56,"is_preprint":false},{"pmid":"17475929","id":"PMC_17475929","title":"Pig conceptuses increase uterine interferon-regulatory factor 1 (IRF1), but restrict expression to stroma through estrogen-induced IRF2 in luminal epithelium.","date":"2007","source":"Biology of reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/17475929","citation_count":56,"is_preprint":false},{"pmid":"7630638","id":"PMC_7630638","title":"Transcription factor IRF-2 exerts its oncogenic phenotype through the DNA binding/transcription repression domain.","date":"1995","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/7630638","citation_count":53,"is_preprint":false},{"pmid":"18291530","id":"PMC_18291530","title":"Gene structures and promoter characteristics of interferon regulatory factor 1 (IRF-1), IRF-2 and IRF-7 from snakehead Channa argus.","date":"2008","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/18291530","citation_count":47,"is_preprint":false},{"pmid":"26173586","id":"PMC_26173586","title":"MicroRNA-18a modulates P53 expression by targeting IRF2 in gastric cancer patients.","date":"2016","source":"Journal of gastroenterology and hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/26173586","citation_count":46,"is_preprint":false},{"pmid":"16241857","id":"PMC_16241857","title":"Interferon regulatory factor 1 (IRF-1) and IRF-2 expression in breast cancer tissue microarrays.","date":"2005","source":"Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research","url":"https://pubmed.ncbi.nlm.nih.gov/16241857","citation_count":44,"is_preprint":false},{"pmid":"17059692","id":"PMC_17059692","title":"Transcriptional regulation of lipopolysaccharide (LPS)-induced Toll-like receptor (TLR) expression in murine macrophages: role of interferon regulatory factors 1 (IRF-1) and 2 (IRF-2).","date":"2006","source":"Journal of endotoxin research","url":"https://pubmed.ncbi.nlm.nih.gov/17059692","citation_count":42,"is_preprint":false},{"pmid":"35212366","id":"PMC_35212366","title":"Characterisation of the Circulating Transcriptomic Landscape in Inflammatory Bowel Disease Provides Evidence for Dysregulation of Multiple Transcription Factors Including NFE2, SPI1, CEBPB, and IRF2.","date":"2022","source":"Journal of Crohn's & colitis","url":"https://pubmed.ncbi.nlm.nih.gov/35212366","citation_count":41,"is_preprint":false},{"pmid":"25463511","id":"PMC_25463511","title":"Ctenopharyngodon idella IRF2 plays an antagonistic role to IRF1 in transcriptional regulation of IFN and ISG genes.","date":"2014","source":"Developmental and comparative immunology","url":"https://pubmed.ncbi.nlm.nih.gov/25463511","citation_count":38,"is_preprint":false},{"pmid":"30127908","id":"PMC_30127908","title":"miR-18a-5p promotes cell invasion and migration of osteosarcoma by directly targeting IRF2.","date":"2018","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/30127908","citation_count":37,"is_preprint":false},{"pmid":"25960866","id":"PMC_25960866","title":"Division of labor between IRF1 and IRF2 in regulating different stages of transcriptional activation in cellular antiviral activities.","date":"2015","source":"Cell & bioscience","url":"https://pubmed.ncbi.nlm.nih.gov/25960866","citation_count":37,"is_preprint":false},{"pmid":"22114555","id":"PMC_22114555","title":"A gammaherpesvirus cooperates with interferon-alpha/beta-induced IRF2 to halt viral replication, control reactivation, and minimize host lethality.","date":"2011","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/22114555","citation_count":37,"is_preprint":false},{"pmid":"33735820","id":"PMC_33735820","title":"IRF2 regulates cellular survival and Lenvatinib-sensitivity of hepatocellular carcinoma (HCC) through regulating β-catenin.","date":"2021","source":"Translational oncology","url":"https://pubmed.ncbi.nlm.nih.gov/33735820","citation_count":36,"is_preprint":false},{"pmid":"19032150","id":"PMC_19032150","title":"Role of Mdm2 acid domain interactions in recognition and ubiquitination of the transcription factor IRF-2.","date":"2009","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/19032150","citation_count":35,"is_preprint":false},{"pmid":"18395009","id":"PMC_18395009","title":"IRF-2 regulates NF-kappaB activity by modulating the subcellular localization of NF-kappaB.","date":"2008","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/18395009","citation_count":33,"is_preprint":false},{"pmid":"28320935","id":"PMC_28320935","title":"Triad of human cellular proteins, IRF2, FAM111A, and RFC3, restrict replication of orthopoxvirus SPI-1 host-range mutants.","date":"2017","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/28320935","citation_count":32,"is_preprint":false},{"pmid":"28512062","id":"PMC_28512062","title":"Hsa-miR-513b-5p suppresses cell proliferation and promotes P53 expression by targeting IRF2 in testicular embryonal carcinoma cells.","date":"2017","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/28512062","citation_count":31,"is_preprint":false},{"pmid":"11721886","id":"PMC_11721886","title":"Mutation and association analysis of the interferon regulatory factor 2 gene (IRF2) with atopic dermatitis.","date":"2001","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11721886","citation_count":31,"is_preprint":false},{"pmid":"9540062","id":"PMC_9540062","title":"The integrated activities of IRF-2 (HiNF-M), CDP/cut (HiNF-D) and H4TF-2 (HiNF-P) regulate transcription of a cell cycle controlled human histone H4 gene: mechanistic differences between distinct H4 genes.","date":"1998","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/9540062","citation_count":30,"is_preprint":false},{"pmid":"16871414","id":"PMC_16871414","title":"Gene structure and transcription of IRF-2 in the mandarin fish Siniperca chuatsi with the finding of alternative transcripts and microsatellite in the coding region.","date":"2006","source":"Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/16871414","citation_count":29,"is_preprint":false},{"pmid":"18514056","id":"PMC_18514056","title":"Regulation of IRF2 transcriptional activity by its sumoylation.","date":"2008","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/18514056","citation_count":28,"is_preprint":false},{"pmid":"14962090","id":"PMC_14962090","title":"Evaluation of the IRF-2 gene as a candidate for PSORS3.","date":"2004","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/14962090","citation_count":28,"is_preprint":false},{"pmid":"21703300","id":"PMC_21703300","title":"Molecular cloning and characterization of interferon regulatory factor 1 (IRF-1), IRF-2 and IRF-5 in the chondrostean paddlefish Polyodon spathula and their phylogenetic importance in the Osteichthyes.","date":"2011","source":"Developmental and comparative immunology","url":"https://pubmed.ncbi.nlm.nih.gov/21703300","citation_count":28,"is_preprint":false},{"pmid":"22119988","id":"PMC_22119988","title":"IRF-2 is over-expressed in pancreatic cancer and promotes the growth of pancreatic cancer cells.","date":"2011","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22119988","citation_count":28,"is_preprint":false},{"pmid":"19170204","id":"PMC_19170204","title":"Intratumoral interferon regulatory factor (IRF)-1 but not IRF-2 is of relevance in predicting patient outcome in ovarian cancer.","date":"2009","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/19170204","citation_count":27,"is_preprint":false},{"pmid":"32655783","id":"PMC_32655783","title":"LncRNA LINC00265/miR-485-5p/IRF2-mediated autophagy suppresses apoptosis in acute myeloid leukemia cells.","date":"2020","source":"American journal of translational research","url":"https://pubmed.ncbi.nlm.nih.gov/32655783","citation_count":25,"is_preprint":false},{"pmid":"34022918","id":"PMC_34022918","title":"LncRNA GAS5 modulates the progression of non-small cell lung cancer through repressing miR-221-3p and up-regulating IRF2.","date":"2021","source":"Diagnostic pathology","url":"https://pubmed.ncbi.nlm.nih.gov/34022918","citation_count":25,"is_preprint":false},{"pmid":"12474233","id":"PMC_12474233","title":"Psoriatic lesional skin exhibits an aberrant expression pattern of interferon regulatory factor-2 (IRF-2).","date":"2003","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/12474233","citation_count":25,"is_preprint":false},{"pmid":"34878155","id":"PMC_34878155","title":"IRF2 contributes to myocardial infarction via regulation of GSDMD induced pyroptosis.","date":"2021","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/34878155","citation_count":25,"is_preprint":false},{"pmid":"28467773","id":"PMC_28467773","title":"miR-302b inhibits cancer-related inflammation by targeting ERBB4, IRF2 and CXCR4 in esophageal cancer.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/28467773","citation_count":24,"is_preprint":false},{"pmid":"33264494","id":"PMC_33264494","title":"Circular RNA hsa_circ_0000658 inhibits osteosarcoma cell proliferation and migration via the miR-1227/IRF2 axis.","date":"2020","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33264494","citation_count":24,"is_preprint":false},{"pmid":"30876449","id":"PMC_30876449","title":"IRF2-INPP4B-mediated autophagy suppresses apoptosis in acute myeloid leukemia cells.","date":"2019","source":"Biological research","url":"https://pubmed.ncbi.nlm.nih.gov/30876449","citation_count":24,"is_preprint":false},{"pmid":"27677680","id":"PMC_27677680","title":"Expression and functional characterization of interferon regulatory factors (irf2, irf7 and irf9) in the blunt snout bream (Megalobrama amblycephala).","date":"2016","source":"Developmental and comparative immunology","url":"https://pubmed.ncbi.nlm.nih.gov/27677680","citation_count":24,"is_preprint":false},{"pmid":"23422814","id":"PMC_23422814","title":"Molecular characterization of interferon regulatory factor 2 (IRF-2) homolog in pearl oyster Pinctada fucata.","date":"2013","source":"Fish & shellfish immunology","url":"https://pubmed.ncbi.nlm.nih.gov/23422814","citation_count":24,"is_preprint":false},{"pmid":"18207304","id":"PMC_18207304","title":"Homeostatic erythropoiesis by the transcription factor IRF2 through attenuation of type I interferon signaling.","date":"2008","source":"Experimental hematology","url":"https://pubmed.ncbi.nlm.nih.gov/18207304","citation_count":23,"is_preprint":false},{"pmid":"12493643","id":"PMC_12493643","title":"The IRF-2 DNA binding domain facilitates the activation of the class II transactivator (CIITA) type IV promoter by IRF-1.","date":"2003","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12493643","citation_count":23,"is_preprint":false},{"pmid":"9562558","id":"PMC_9562558","title":"Solution structure of the IRF-2 DNA-binding domain: a novel subgroup of the winged helix-turn-helix family.","date":"1998","source":"Structure (London, England : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/9562558","citation_count":23,"is_preprint":false},{"pmid":"17073600","id":"PMC_17073600","title":"The role of IRF1 and IRF2 transcription factors in leukaemogenesis.","date":"2006","source":"Current gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/17073600","citation_count":22,"is_preprint":false},{"pmid":"25994869","id":"PMC_25994869","title":"Genetic association of key Th1/Th2 pathway candidate genes, IRF2, IL6, IFNGR2, STAT4 and IL4RA, with atopic asthma in the Indian population.","date":"2015","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25994869","citation_count":22,"is_preprint":false},{"pmid":"8475044","id":"PMC_8475044","title":"Characterization of the DNA binding domain of the mouse IRF-2 protein.","date":"1993","source":"Protein engineering","url":"https://pubmed.ncbi.nlm.nih.gov/8475044","citation_count":22,"is_preprint":false},{"pmid":"28970238","id":"PMC_28970238","title":"HCFC2 is needed for IRF1- and IRF2-dependent Tlr3 transcription and for survival during viral infections.","date":"2017","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28970238","citation_count":20,"is_preprint":false},{"pmid":"11559933","id":"PMC_11559933","title":"Alterations in IRF1/IRF2 expression in acute myelogenous leukemia.","date":"2001","source":"American journal of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/11559933","citation_count":20,"is_preprint":false},{"pmid":"18671972","id":"PMC_18671972","title":"IRF2-binding protein-1 is a JDP2 ubiquitin ligase and an inhibitor of ATF2-dependent transcription.","date":"2008","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/18671972","citation_count":20,"is_preprint":false},{"pmid":"34185419","id":"PMC_34185419","title":"IRF2-mediated upregulation of lncRNA HHAS1 facilitates the osteogenic differentiation of bone marrow-derived mesenchymal stem cells by acting as a competing endogenous RNA.","date":"2021","source":"Clinical and translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34185419","citation_count":20,"is_preprint":false},{"pmid":"9213219","id":"PMC_9213219","title":"Phosphorylation of the oncogenic transcription factor interferon regulatory factor 2 (IRF2) in vitro and in vivo.","date":"1997","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9213219","citation_count":20,"is_preprint":false},{"pmid":"20129639","id":"PMC_20129639","title":"Interferon regulatory factor (IRF)-2 activates the HPV-16 E6-E7 promoter in keratinocytes.","date":"2010","source":"Virology","url":"https://pubmed.ncbi.nlm.nih.gov/20129639","citation_count":20,"is_preprint":false},{"pmid":"31611556","id":"PMC_31611556","title":"IRF2 is a master regulator of human keratinocyte stem cell fate.","date":"2019","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/31611556","citation_count":19,"is_preprint":false},{"pmid":"34992348","id":"PMC_34992348","title":"Downregulation of IRF2 Alleviates Sepsis-Related Acute Kidney Injury in vitro and in vivo.","date":"2021","source":"Drug design, development and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/34992348","citation_count":19,"is_preprint":false},{"pmid":"29386090","id":"PMC_29386090","title":"[ARTICLE WITHDRAWN] MicroRNA-18a Targets IRF2 and CBX7 to Promote Cell Proliferation in Hepatocellular Carcinoma.","date":"2018","source":"Oncology research","url":"https://pubmed.ncbi.nlm.nih.gov/29386090","citation_count":19,"is_preprint":false},{"pmid":"28203525","id":"PMC_28203525","title":"MicroRNA-520c enhances cell proliferation, migration, and invasion by suppressing IRF2 in gastric cancer.","date":"2016","source":"FEBS open bio","url":"https://pubmed.ncbi.nlm.nih.gov/28203525","citation_count":18,"is_preprint":false},{"pmid":"18575764","id":"PMC_18575764","title":"siRNA targeting the IRF2 transcription factor inhibits leukaemic cell growth.","date":"2008","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/18575764","citation_count":18,"is_preprint":false},{"pmid":"31934069","id":"PMC_31934069","title":"LncRNA XIST, as a ceRNA of miR-204, aggravates lipopolysaccharide-induced acute respiratory distress syndrome in mice by upregulating IRF2.","date":"2019","source":"International journal of clinical and experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/31934069","citation_count":18,"is_preprint":false},{"pmid":"31379068","id":"PMC_31379068","title":"IRF1 and IRF2 regulate the non-canonical inflammasome.","date":"2019","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/31379068","citation_count":17,"is_preprint":false},{"pmid":"31350707","id":"PMC_31350707","title":"IRF-2 Inhibits Gastric Cancer Invasion and Migration by Down-Regulating MMP-1.","date":"2019","source":"Digestive diseases and sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31350707","citation_count":17,"is_preprint":false},{"pmid":"8713742","id":"PMC_8713742","title":"IRF-1 and IRF-2 as regulators of the interferon system and cell growth.","date":"1995","source":"Indian journal of biochemistry & biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/8713742","citation_count":17,"is_preprint":false},{"pmid":"22042864","id":"PMC_22042864","title":"Characterization of dsRNA-induced pancreatitis model reveals the regulatory role of IFN regulatory factor 2 (Irf2) in trypsinogen5 gene transcription.","date":"2011","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/22042864","citation_count":17,"is_preprint":false},{"pmid":"33444646","id":"PMC_33444646","title":"IRF1 and IRF2 act as positive regulators in antiviral response of large yellow croaker (Larimichthys crocea) by induction of distinct subgroups of type I IFNs.","date":"2021","source":"Developmental and comparative immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33444646","citation_count":16,"is_preprint":false},{"pmid":"26545324","id":"PMC_26545324","title":"Fish IRF3 up-regulates the transcriptional level of IRF1, IRF2, IRF3 and IRF7 in CIK cells.","date":"2015","source":"Fish & shellfish immunology","url":"https://pubmed.ncbi.nlm.nih.gov/26545324","citation_count":16,"is_preprint":false},{"pmid":"23554911","id":"PMC_23554911","title":"Up-regulation of intestinal epithelial cell derived IL-7 expression by keratinocyte growth factor through STAT1/IRF-1, IRF-2 pathway.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23554911","citation_count":16,"is_preprint":false},{"pmid":"30017925","id":"PMC_30017925","title":"Regulation of IL-17 by lncRNA of IRF-2 in the pearl oyster.","date":"2018","source":"Fish & shellfish immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30017925","citation_count":16,"is_preprint":false},{"pmid":"16007130","id":"PMC_16007130","title":"A retroviral library genetic screen identifies IRF-2 as an inhibitor of N-ras-induced growth suppression in leukemic cells.","date":"2005","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/16007130","citation_count":16,"is_preprint":false},{"pmid":"28579269","id":"PMC_28579269","title":"IRF2-INPP4B axis participates in the development of acute myeloid leukemia by regulating cell growth and survival.","date":"2017","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/28579269","citation_count":15,"is_preprint":false},{"pmid":"12537697","id":"PMC_12537697","title":"The role of the interferon regulatory factors, IRF-1 and IRF-2, in LPS-induced cyclooxygenase-2 (COX-2) expression in vivo and in vitro.","date":"2002","source":"Journal of endotoxin research","url":"https://pubmed.ncbi.nlm.nih.gov/12537697","citation_count":15,"is_preprint":false},{"pmid":"32901054","id":"PMC_32901054","title":"IRF2 maintains the stemness of colonic stem cells by limiting physiological stress from interferon.","date":"2020","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/32901054","citation_count":15,"is_preprint":false},{"pmid":"34930359","id":"PMC_34930359","title":"IRF2 inhibits ZIKV replication by promoting FAM111A expression to enhance the host restriction effect of RFC3.","date":"2021","source":"Virology journal","url":"https://pubmed.ncbi.nlm.nih.gov/34930359","citation_count":13,"is_preprint":false},{"pmid":"34423051","id":"PMC_34423051","title":"Propofol Ameliorates Microglia Activation by Targeting MicroRNA-221/222-IRF2 Axis.","date":"2021","source":"Journal of immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/34423051","citation_count":13,"is_preprint":false},{"pmid":"22773153","id":"PMC_22773153","title":"IRF-2 regulates B-cell proliferation and antibody production through distinct mechanisms.","date":"2012","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/22773153","citation_count":13,"is_preprint":false},{"pmid":"10942060","id":"PMC_10942060","title":"The interferon-alpha regulation of interferon regulatory factor 1 (IRF-1) and IRF-2 has therapeutic implications in carcinoid tumors.","date":"2000","source":"Annals of oncology : official journal of the European Society for Medical Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/10942060","citation_count":13,"is_preprint":false},{"pmid":"19962964","id":"PMC_19962964","title":"SUMOylated IRF-1 shows oncogenic potential by mimicking IRF-2.","date":"2009","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/19962964","citation_count":13,"is_preprint":false},{"pmid":"37607223","id":"PMC_37607223","title":"Bcl6, Irf2, and Notch2 promote nonclassical monocyte development.","date":"2023","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/37607223","citation_count":12,"is_preprint":false},{"pmid":"36314827","id":"PMC_36314827","title":"IRF2 Cooperates with Phosphoprotein of Spring Viremia of Carp Virus to Suppress Antiviral Response in Zebrafish.","date":"2022","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/36314827","citation_count":12,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":50172,"output_tokens":7913,"usd":0.134605},"stage2":{"model":"claude-opus-4-6","input_tokens":11677,"output_tokens":4172,"usd":0.244028},"total_usd":0.378633,"stage1_batch_id":"msgbatch_01DzrsgVgYngY1hvM3DU1yF2","stage2_batch_id":"msgbatch_01KA9b7iRzKFdhoBUT7vCvSe","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1989,\n      \"finding\": \"IRF-2 was identified as a transcription factor that binds to the same regulatory cis-elements as IRF-1 within IFN and IFN-inducible gene promoters, but functions as a transcriptional repressor rather than an activator, suppressing IRF-1 function by competing for the same binding sequences.\",\n      \"method\": \"cDNA cloning, DNA binding assays, transcriptional reporter assays, competition experiments\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — original discovery paper with multiple orthogonal methods, foundational work replicated across hundreds of subsequent studies\",\n      \"pmids\": [\"2475256\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"The DNA recognition sequences of IRF-1 and IRF-2 are virtually indistinguishable; both factors bind the same consensus sequences within IFN and IFN-inducible gene promoters with similar affinities, as determined by PCR-assisted DNA-binding site selection.\",\n      \"method\": \"PCR-assisted DNA binding site selection, EMSA\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — biochemical determination of DNA recognition sequences with rigorous controls\",\n      \"pmids\": [\"7687740\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"Targeted disruption of IRF-2 in mice results in up-regulated type I IFN induction following NDV infection, demonstrating that IRF-2 functions as a negative regulator of IFN gene transcription in vivo. IRF-2 knockout mice also exhibit bone marrow suppression of hematopoiesis and B lymphopoiesis.\",\n      \"method\": \"Gene targeting in embryonic stem cells, knockout mice, viral infection assays\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO with defined cellular and molecular phenotype, replicated across labs\",\n      \"pmids\": [\"8402903\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"IRF-2 possesses a transcriptional repression domain in its carboxyl-terminal region and a latent activation domain in its central region. Repression by IRF-2 involves both competition with IRF-1 for promoter binding and silencing of nearby activators via a LexA fusion approach.\",\n      \"method\": \"Deletion mapping, LexA fusion transcriptional assays, reporter gene assays\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — domain mapping with mutagenesis and functional validation\",\n      \"pmids\": [\"8152803\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"The human IRF-2 gene is located at chromosome 4q35.1. The IRF-2 promoter contains an IRF binding site, and IRF-2 gene expression is regulated by IRF-1, establishing a gene network for autoregulation of the IFN system.\",\n      \"method\": \"FISH chromosomal mapping, promoter analysis, transient and stable transfection\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct experimental mapping and promoter functional validation\",\n      \"pmids\": [\"7507207\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"IRF-2 (identified as histone nuclear factor M, HiNF-M) was purified and shown to be a 48 kDa protein that binds the cell cycle element (CCE) in the human histone H4 gene promoter and activates its transcription, linking IRF-2 to cell cycle-regulated gene expression at the G1/S transition.\",\n      \"method\": \"Protein purification, EMSA, transcriptional reporter assays, recombinant protein binding\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — protein purification, identity confirmation, and functional transcriptional assay\",\n      \"pmids\": [\"7566094\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"The oncogenic activity of IRF-2 maps to its N-terminal DNA binding/transcriptional repression domain (first 160 amino acids). Overexpression of wild-type or truncated IRF-2 transforms NIH3T3 cells in vitro and promotes tumor formation in vivo.\",\n      \"method\": \"C-terminal deletion mutagenesis, NIH3T3 transformation assay, soft agar colony assay, nude mouse tumor formation\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — systematic domain mutagenesis with multiple functional readouts in vitro and in vivo\",\n      \"pmids\": [\"7630638\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"IRF-2 is phosphorylated in vivo on serine residues. In vitro, recombinant IRF-2 is a substrate for PKA, PKC, and CK2, but not for JNK1, p38, or ERK2, indicating selective kinase regulation of IRF-2.\",\n      \"method\": \"In vivo 32P labeling with immunoprecipitation, in vitro kinase assays, 2D phosphopeptide mapping, phosphoamino acid analysis\",\n      \"journal\": \"Journal of cellular biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro kinase assay combined with in vivo phosphorylation validation\",\n      \"pmids\": [\"9213219\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Cell cycle regulation of histone H4 gene transcription requires IRF-2. IRF-2-null embryonic fibroblasts lose stringent cell cycle control of histone H4 expression, and reintroduction of IRF-2 restores both mRNA levels and cell cycle-regulated transcription.\",\n      \"method\": \"IRF-2 knockout fibroblasts, synchronized cell culture, mRNA analysis, complementation with IRF-2 re-expression\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO with functional rescue experiment and defined molecular phenotype\",\n      \"pmids\": [\"9417064\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"The solution structure of the IRF-2 DNA-binding domain (DBD) was determined by NMR spectroscopy. The DBD adopts a winged helix-turn-helix (wHTH) fold with a four-stranded antiparallel beta sheet and three alpha helices. A long loop (Pro37-Asp51) and the second helix of the HTH motif participate in DNA recognition.\",\n      \"method\": \"NMR spectroscopy, DNA binding experiments\",\n      \"journal\": \"Structure\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — NMR structure determination with DNA binding validation\",\n      \"pmids\": [\"9562558\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"IRF-2 acts as a transcriptional repressor of the 2-5A synthetase and p21 gene promoters by direct binding to promoter IRF elements, counterbalancing IRF-1 activation. IRF-1 also induces IRF-2 expression via an IRF-E element in the IRF-2 promoter, establishing an autoinhibitory feedback loop.\",\n      \"method\": \"Ectopic expression, EMSA, cotransfection reporter assays, antisense approach\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct binding and transcriptional reporter assays with functional consequence\",\n      \"pmids\": [\"10321737\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"IRF-2 negatively regulates IFN-alpha/beta-induced gene transcription; CD8+ T cell abnormalities and inflammatory skin disease in IRF-2-deficient mice are suppressed by nullizygosity for genes that positively regulate IFN-alpha/beta signaling, placing IRF-2 as a negative regulator of IFN-alpha/beta signaling in vivo.\",\n      \"method\": \"IRF-2 KO mice, genetic epistasis (double KO with IFN-alpha/beta pathway genes), in vitro T cell assays\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis in vivo with defined pathway placement and cellular phenotype\",\n      \"pmids\": [\"11114377\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"IRF-2 deficiency in macrophages results in increased basal and IFN-gamma-inducible COX-2 mRNA and protein expression, and two IFN stimulation response elements in the COX-2 promoter bind endogenous IRF-2 to repress transcription.\",\n      \"method\": \"IRF-2 KO macrophages, reporter gene assays, EMSA with endogenous protein, COX-2 protein and PGE2 measurement\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — KO macrophages with defined molecular and biochemical phenotype, confirmed by direct promoter binding\",\n      \"pmids\": [\"10859338\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"IFN-gamma-induced IRF-1 and IRF-2 bind to three distinct sites in the IL-4 promoter and function as transcriptional repressors, providing a direct mechanism by which IFN-gamma suppresses Th2 cytokine IL-4 expression.\",\n      \"method\": \"Promoter reporter assays, EMSA, chromatin-IP-like binding studies, CD4+ T cell assays\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct promoter binding and functional repression demonstrated in relevant cell type\",\n      \"pmids\": [\"12479817\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"IRF-2 co-occupies the IRF-E of the CIITA type IV promoter with IRF-1, stabilizing IRF-1 binding and cooperating to activate CIITA transcription. The IRF-2 DNA binding domain is sufficient for cooperative activation with IRF-1, while a latent activation domain in IRF-2 is required for IRF-2 transactivation of this promoter.\",\n      \"method\": \"EMSA, off-rate experiments, deletion analysis, cotransfection reporter assays\",\n      \"journal\": \"Molecular immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — domain mapping with direct DNA binding and functional reporter assays\",\n      \"pmids\": [\"12493643\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Blimp-1, IRF-1, and IRF-2 share similar binding affinities for regulatory sites containing the GAAAG sequence and can compete for the same binding sites in vitro and in vivo, including the IFN-beta promoter, as shown by chromatin immunoprecipitation.\",\n      \"method\": \"Binding competition assays, equilibrium dissociation constant measurement, chromatin immunoprecipitation, cotransfection assays\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — ChIP in vivo plus quantitative in vitro binding characterization\",\n      \"pmids\": [\"15494505\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"IRF-2 regulates NF-kappaB activity by physically interacting with RelA/p65 and promoting its nuclear localization. The N-terminal domain of IRF-2 is required for this interaction; knockdown of IRF-2 attenuates TNFalpha-induced NF-kappaB transcription by inhibiting RelA nuclear translocation.\",\n      \"method\": \"Co-immunoprecipitation, subcellular localization assays, siRNA knockdown, NF-kappaB reporter assays, dominant-negative deletion\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — physical interaction and functional consequence demonstrated, single lab\",\n      \"pmids\": [\"18395009\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"IRF2 is sumoylated in vivo through interaction with the SUMO-E3 ligase PIASy at three sumoylation sites. Sumoylation of IRF2 does not affect nuclear localization or DNA binding but increases its ability to inhibit IRF1 transcriptional activity and decreases its ability to activate ISRE- and H4-driven promoters.\",\n      \"method\": \"Co-IP with PIASy, in vivo sumoylation assay, mutagenesis of sumoylation sites, reporter gene assays, subcellular localization, DNA binding assays\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — identification of writer (PIASy), sites mapped by mutagenesis, functional consequences measured\",\n      \"pmids\": [\"18514056\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"IRF2 is a substrate of Mdm2 E3-ubiquitin ligase. Mdm2-mediated ubiquitination of IRF2 requires interaction at both the hydrophobic pocket and the acid domain of Mdm2, mirroring the dual-site mechanism used for p53. IRF2-Mdm2 complex formation occurs in cells.\",\n      \"method\": \"Bioinformatics, in vitro ubiquitination assay, mutagenesis of Mdm2-binding sites on IRF2, co-immunoprecipitation in cells\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted in vitro ubiquitination assay with mutagenesis validation and in-cell co-IP\",\n      \"pmids\": [\"19032150\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"IRF2 maintains normal erythropoiesis by attenuating type I IFN signaling. Additional homozygous deletion of IFNAR1 in Irf2-deficient mice rescues the erythropoiesis defect, establishing IRF2 as a regulator of homeostatic erythropoiesis through negative regulation of type I IFN signaling in erythroid cells.\",\n      \"method\": \"IRF-2 KO mice, double KO epistasis (Irf2-/-; Ifnar1-/-), flow cytometry of erythroid progenitors, Bcl-XL expression analysis\",\n      \"journal\": \"Experimental hematology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis places IRF2 in the IFN-alpha/beta pathway for erythropoiesis regulation\",\n      \"pmids\": [\"18207304\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"IRF2-binding protein-1 (IRF2-BP1), a transcriptional corepressor of IRF2 containing a RING-finger domain, acts as an E3 ubiquitin ligase for JDP2 and represses ATF2-mediated transcription from CRE-containing promoters.\",\n      \"method\": \"Epitope-tag pulldown to identify IRF2-BP1 as JDP2-binding protein, ubiquitination assay, reporter gene assays\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — biochemical identification of interaction and E3 ligase activity, single lab\",\n      \"pmids\": [\"18671972\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"IRF2 directly binds to an interferon-stimulated response element (ISRE) in the MHV68 M2 gene promoter during latency in vivo and functions as an IFNalphabeta-induced transcriptional repressor of M2, limiting viral reactivation from latency. Virus lacking the M2 ISRE shows IRF2-dependent dysregulated M2 expression and uncontrolled reactivation.\",\n      \"method\": \"ChIP in vivo, ISRE mutant virus (ISREΔ), IRF2 knockout mice, viral load and reactivation assays\",\n      \"journal\": \"PLoS pathogens\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP in vivo, genetic validation with IRF2 KO and ISRE mutant virus\",\n      \"pmids\": [\"22114555\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"IRF2 (not IRF1) is constitutively associated with the TLR3 promoter in unstimulated cells and maintains an open chromatin structure with active histone marks (H3K9/K14 acetylation, H3K4 tri-methylation), while IRF1 binding is induced upon IFN stimulation to drive transcriptional activation. Both IRF1 and IRF2 interact with the BAF chromatin remodeling complex.\",\n      \"method\": \"ChIP assays, histone modification analysis, BAF complex interaction assays, IRF1/IRF2 KO cells, gene expression analysis\",\n      \"journal\": \"Cell & bioscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP and BAF interaction with KO validation, single lab\",\n      \"pmids\": [\"25960866\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"IRF2 regulates basal expression of FAM111A; depletion of IRF2 reduces FAM111A expression, and this is the mechanism by which IRF2 knockdown enhances replication of an SPI-1 deletion orthopoxvirus mutant in human cells. Microarray analysis, qRT-PCR, and immunoblotting confirmed IRF2 as a transcriptional regulator of FAM111A.\",\n      \"method\": \"Genome-wide siRNA screen, secondary screen confirmation, microarray analysis, qRT-PCR, immunoblotting\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional genomic screen with orthogonal validation of IRF2-FAM111A regulatory relationship\",\n      \"pmids\": [\"28320935\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"IRF2 directly binds to a unique site within the GSDMD promoter to drive GSDMD transcription. Loss of IRF2 substantially attenuates GSDMD expression in macrophages and multiple tissues, reducing IL-1beta secretion and inhibiting pyroptosis by both canonical and non-canonical inflammasomes. Disruption of the single IRF2-binding site in the GSDMD promoter abolishes inflammasome signaling.\",\n      \"method\": \"ENU forward genetic screen, IRF2 KO macrophages and tissues, ChIP/promoter binding, site-directed mutagenesis of GSDMD promoter, pyroptosis and IL-1beta secretion assays\",\n      \"journal\": \"Science signaling\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — forward genetic screen + direct promoter binding + mutagenesis + KO phenotype with multiple orthogonal validations\",\n      \"pmids\": [\"31113851\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"A genome-wide CRISPR screen identified IRF2 as essential for caspase-4 expression in human monocytes, establishing IRF2 as a transcriptional activator of CASP4 and thereby a regulator of non-canonical inflammasome-driven pyroptosis following cytosolic LPS delivery. IFN-gamma priming can induce IRF1 to compensate for IRF2 deficiency.\",\n      \"method\": \"Genome-wide CRISPR/Cas9 screen, IRF2 KO human monocytes and iPSC-derived monocytes, caspase-4 expression analysis, pyroptosis assays, bacterial infection\",\n      \"journal\": \"EMBO reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genome-wide unbiased screen, KO validation in primary and iPSC-derived cells, functional pyroptosis readout\",\n      \"pmids\": [\"31353801\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"IRF2 identified in a CRISPR-based forward genetic screen as a transcriptional activator of multiple MHC-I pathway components (immunoproteasomes, TAP, ERAP1) and a transcriptional repressor of PD-L1. Loss of IRF2 impairs cytosol-to-ER peptide transport and N-terminal peptide trimming, reducing antigen presentation.\",\n      \"method\": \"CRISPR forward genetic screen in HeLa cells, IRF2 KO, antigen presentation assays, PD-L1 expression measurement\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — unbiased CRISPR screen with functional KO validation and defined mechanistic pathway\",\n      \"pmids\": [\"31471524\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"KRAS* (oncogenic KRAS) represses IRF2 expression, and IRF2 in turn directly represses CXCL3 expression. KRAS*-mediated loss of IRF2 leads to elevated CXCL3, which promotes MDSC migration to the tumor microenvironment via CXCR2, mediating immune suppression and anti-PD-1 resistance.\",\n      \"method\": \"Enforced IRF2 expression in CRC models, CXCL3 reporter assays, CXCR2 inhibition, anti-PD-1 treatment experiments\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — pathway epistasis established by gain-of-function rescue and pharmacological inhibition with defined molecular cascade\",\n      \"pmids\": [\"30905761\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"IRF-2 overexpression down-regulates IFN-gamma-induced PD-L1 promoter activity and protein levels in hepatocellular carcinoma cells. Two IRF-1 response elements (IRE1 and IRE2) in the PD-L1 (CD274) promoter were identified, and site-directed mutagenesis confirmed both are functional. IRF-2 antagonizes IRF-1 for binding to the IRE promoter element in PD-L1.\",\n      \"method\": \"IRF-2 overexpression, PD-L1 promoter reporter assays, site-directed mutagenesis, protein expression analysis\",\n      \"journal\": \"Cancer immunology, immunotherapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — promoter mutagenesis with functional reporter validation, single lab\",\n      \"pmids\": [\"32377817\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"IRF2 maintains stemness of colonic stem cells by limiting IFN signaling. Conditional intestinal epithelial deletion of Irf2 (Irf2ΔIEC mice) reduces colonic stem cell numbers and organoid-forming potential, with premature differentiation into transit-amplifying cells, and impairs colon epithelium regeneration after colitis.\",\n      \"method\": \"Conditional KO mice (Irf2ΔIEC), organoid assay, flow cytometry, poly(I:C) injection model, DSS colitis model\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — tissue-specific conditional KO with multiple functional readouts and mechanistic link to IFN signaling\",\n      \"pmids\": [\"32901054\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"IRF2 directly binds to the GSDMD promoter (confirmed by ChIP and dual-luciferase reporter assay) to drive GSDMD transcription and promote pyroptosis in cardiomyocytes during myocardial infarction. IRF2 expression in this context may be regulated by HIF-1 signaling.\",\n      \"method\": \"ChIP, dual-luciferase reporter assay, IRF2 silencing in hypoxia model, MI mouse model\",\n      \"journal\": \"Molecular medicine reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct promoter binding confirmed by ChIP and mutagenesis, functional KD phenotype\",\n      \"pmids\": [\"34878155\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"IRF2 transcriptionally activates CENP-N expression by binding its promoter (confirmed by ChIP and dual luciferase reporter assays). CENP-N in turn forms a complex with AKT (confirmed by co-IP and GST pulldown) to regulate glucose metabolism, proliferation, and apoptosis in nasopharyngeal carcinoma cells.\",\n      \"method\": \"ChIP, dual luciferase reporter assay, co-IP, GST pulldown, siRNA knockdown, overexpression\",\n      \"journal\": \"Journal of experimental & clinical cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP and co-IP with functional validation, single lab\",\n      \"pmids\": [\"34893086\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"IRF2 expression in CD8+ T cells is driven by sustained IFN signaling within tumors. CD8+ T cell-specific deletion of IRF2 prevents acquisition of the T cell exhaustion transcriptional program and instead enables sustained effector functions, promoting long-term tumor control. The tumor control by IRF2-deficient CD8+ T cells requires integration of both type I and type II IFN signals.\",\n      \"method\": \"CD8+ T cell-specific IRF2 KO, adoptive transfer, tumor models, transcriptional profiling, checkpoint blockade and adoptive cell therapy experiments\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — cell type-specific KO with defined transcriptional program and functional tumor control phenotype\",\n      \"pmids\": [\"36370712\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"HCFC2 promotes the binding of IRF2 (and IRF1) to the Tlr3 promoter; without HCFC2, IRF2 cannot effectively bind the Tlr3 promoter, and a large subset of IRF2-dependent interferon-regulated genes fails to be transcribed properly. HCFC2 mutations were identified by ENU mutagenesis and confirmed to compromise poly(I:C) responses and viral survival.\",\n      \"method\": \"ENU mutagenesis screen, ChIP for IRF1/IRF2 binding at Tlr3 promoter, macrophage functional assays, viral survival assays\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo ENU screen with ChIP validation establishing HCFC2 as a cofactor for IRF2 promoter binding\",\n      \"pmids\": [\"28970238\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"IRF2 is required cell-intrinsically for the development of Ly6Clo nonclassical monocytes. DLL1-induced NOTCH2 signaling can drive Ly6Chi to Ly6Clo monocyte transition in vitro, and this transition requires IRF2 but can occur in the absence of NUR77 or BCL6, placing IRF2 downstream of NOTCH2 in a transcriptional hierarchy for nonclassical monocyte development.\",\n      \"method\": \"IRF2 KO mice, myeloid progenitor-specific deletions, in vitro DLL1-induced transition assay, flow cytometry\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis with cell-intrinsic KO and defined developmental phenotype\",\n      \"pmids\": [\"37607223\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"IRF2 is a winged helix-turn-helix transcription factor that binds the same regulatory elements as the activator IRF1, primarily functioning as a transcriptional repressor of IFN-stimulated genes by competing for promoter occupancy and recruiting repressive activity through its C-terminal domain; however, it also acts as a transcriptional activator of specific targets including histone H4, GSDMD, CASP4, and MHC-I pathway genes, and its activity is modulated post-translationally by phosphorylation (via PKA, PKC, CK2), SUMOylation (via PIASy), and ubiquitination (via Mdm2), while in vivo it is essential for attenuating type I IFN signaling to maintain erythropoiesis, colonic stem cell homeostasis, and normal immune cell development (NK cells, nonclassical monocytes, B cells), and drives CD8+ T cell exhaustion in tumors through sustained IFN feedback.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"IRF2 is a winged helix-turn-helix transcription factor that functions as both a transcriptional repressor and activator, serving as a central modulator of interferon signaling, innate immune gene expression, cell cycle control, and immune cell differentiation. IRF2 binds the same ISRE/IRF-E consensus elements as the activator IRF1 with virtually indistinguishable affinity and represses IFN-stimulated genes by competitive promoter occupancy and through a C-terminal repression domain, while a latent activation domain enables it to directly activate transcription of histone H4, GSDMD, CASP4, CIITA, and MHC-I pathway genes [PMID:2475256, PMID:7687740, PMID:8152803, PMID:7566094, PMID:31113851, PMID:31471524]. Its activity is modulated by phosphorylation (PKA, PKC, CK2), SUMOylation via PIASy that enhances repressor function, and Mdm2-mediated ubiquitination [PMID:9213219, PMID:18514056, PMID:19032150]. In vivo, IRF2 is essential for attenuating type I IFN signaling to maintain homeostatic erythropoiesis, colonic stem cell renewal, B lymphopoiesis, nonclassical monocyte development, and NK/CD8+ T cell homeostasis; within tumors, sustained IFN-driven IRF2 expression in CD8+ T cells promotes the exhaustion transcriptional program, and its deletion restores effector function and long-term tumor control [PMID:8402903, PMID:11114377, PMID:18207304, PMID:32901054, PMID:37607223, PMID:36370712].\",\n  \"teleology\": [\n    {\n      \"year\": 1989,\n      \"claim\": \"The discovery that IRF2 binds the same IFN regulatory elements as IRF1 yet functions as a repressor established the paradigm of antagonistic IRF pairing in IFN gene regulation.\",\n      \"evidence\": \"cDNA cloning with DNA binding and transcriptional reporter competition assays in Cell\",\n      \"pmids\": [\"2475256\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Repression mechanism not resolved — competitive displacement vs. active silencing unclear\", \"No in vivo validation at this stage\"]\n    },\n    {\n      \"year\": 1993,\n      \"claim\": \"Demonstration that IRF1 and IRF2 recognize virtually identical DNA sequences, combined with the phenotype of IRF2 knockout mice showing exaggerated IFN induction and impaired hematopoiesis, proved that IRF2 is a physiological brake on IFN signaling and hematopoietic homeostasis in vivo.\",\n      \"evidence\": \"PCR-assisted binding site selection (EMSA) and targeted gene disruption in mice\",\n      \"pmids\": [\"7687740\", \"8402903\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cell-type-specific contributions of IRF2 not resolved\", \"Mechanism linking IFN derepression to bone marrow suppression unknown\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Mapping of a C-terminal repression domain and a latent central activation domain within IRF2 resolved how a single factor can act as both repressor and context-dependent activator.\",\n      \"evidence\": \"Deletion mapping and LexA fusion transcriptional assays\",\n      \"pmids\": [\"8152803\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Corepressor/coactivator identity unknown\", \"Whether both domains function simultaneously or are context-switched not determined\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Identification of IRF2 as the long-sought histone H4 activator HiNF-M revealed that IRF2 has bona fide transcriptional activator function at a cell cycle–regulated promoter, fundamentally expanding its role beyond IFN repression.\",\n      \"evidence\": \"Protein purification from HeLa nuclei, identity confirmation, EMSA, and transcriptional reporter assays\",\n      \"pmids\": [\"7566094\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cell cycle–dependent regulation of IRF2 activity not mechanistically explained\", \"Chromatin context of activation not addressed\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Demonstration that IRF2 is phosphorylated in vivo and selectively targeted by PKA, PKC, and CK2 in vitro established post-translational modification as a regulatory layer for IRF2 activity.\",\n      \"evidence\": \"In vivo 32P labeling, immunoprecipitation, in vitro kinase assays, 2D phosphopeptide mapping\",\n      \"pmids\": [\"9213219\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of specific phosphorylation events on DNA binding or transcription not determined\", \"In vivo kinase-IRF2 relationships not validated genetically\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"NMR determination of the IRF2 DNA-binding domain structure revealed a winged helix-turn-helix fold and identified specific residues mediating DNA recognition, providing the first atomic-resolution understanding of IRF-DNA interaction.\",\n      \"evidence\": \"NMR spectroscopy of the IRF2 DBD\",\n      \"pmids\": [\"9562558\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full-length IRF2 structure not solved\", \"Co-crystal with DNA not obtained at this point\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Rescue of histone H4 cell cycle regulation by IRF2 re-expression in knockout fibroblasts demonstrated that IRF2 is required, not merely sufficient, for coupling H4 transcription to S-phase entry.\",\n      \"evidence\": \"IRF2 KO fibroblasts synchronized in culture with complementation rescue\",\n      \"pmids\": [\"9417064\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct mechanism linking IRF2 to cell cycle machinery not identified\", \"Whether IRF2 senses cell cycle signals directly or via upstream regulation unknown\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Genetic epistasis showing that CD8+ T cell and skin disease phenotypes of IRF2 KO mice are rescued by loss of IFN-α/β pathway genes firmly placed IRF2 as a negative regulator of type I IFN signaling in vivo, and loss of IRF2 in macrophages derepressed COX-2 through direct promoter binding, expanding the target repertoire.\",\n      \"evidence\": \"Double-KO genetic epistasis in mice; ChIP and EMSA on COX-2 promoter in KO macrophages\",\n      \"pmids\": [\"11114377\", \"10859338\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether IRF2 regulates type I IFN signaling transcriptionally or post-transcriptionally not fully dissected\", \"COX-2 regulation not tested in non-macrophage lineages\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Identification of SUMOylation by PIASy (enhancing repressor function) and ubiquitination by Mdm2, together with the physical interaction with RelA/p65 promoting NF-κB nuclear translocation, revealed a multi-layered post-translational regulatory network controlling IRF2 activity and expanded its role beyond classical IRF-E targets.\",\n      \"evidence\": \"In vivo SUMOylation assays with site mutagenesis; reconstituted in vitro Mdm2-dependent ubiquitination; co-IP of IRF2-RelA and NF-κB reporter assays with siRNA knockdown\",\n      \"pmids\": [\"18514056\", \"19032150\", \"18395009\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological triggers for SUMOylation and ubiquitination unknown\", \"RelA interaction not validated by reciprocal endogenous co-IP in multiple cell types\", \"Functional interplay between SUMOylation and ubiquitination not tested\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Genetic epistasis (Irf2−/−;Ifnar1−/− double KO) rescuing the erythropoiesis defect of IRF2 KO mice established that IRF2 maintains homeostatic erythropoiesis specifically by attenuating type I IFN receptor signaling in erythroid progenitors.\",\n      \"evidence\": \"Double-KO mice with flow cytometric analysis of erythroid progenitors and Bcl-XL measurement\",\n      \"pmids\": [\"18207304\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct IRF2 target genes in erythroid progenitors not identified\", \"Whether IRF2 acts cell-autonomously in erythroid cells not formally proven with conditional KO\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"ChIP studies showing constitutive IRF2 occupancy at the TLR3 promoter maintaining open chromatin with active histone marks, and interaction with the BAF remodeling complex, revealed a chromatin-architectural role for IRF2 at baseline that primes gene expression prior to IFN stimulation.\",\n      \"evidence\": \"ChIP for IRF2 and histone marks, BAF complex interaction assays, IRF1/IRF2 KO cell expression analysis\",\n      \"pmids\": [\"25960866\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"BAF subunit specificity for IRF2 interaction not determined\", \"Genome-wide extent of this chromatin-priming role unknown\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"HCFC2 was identified as a cofactor required for IRF2 binding to the Tlr3 promoter and a large subset of IRF2-dependent IFN-regulated genes, revealing that IRF2 promoter occupancy is not solely determined by its intrinsic DNA-binding properties but requires accessory factors.\",\n      \"evidence\": \"ENU mutagenesis screen in mice, ChIP for IRF2 at Tlr3 promoter with and without HCFC2, macrophage poly(I:C) response and viral survival assays\",\n      \"pmids\": [\"28320935\", \"28970238\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of HCFC2-IRF2 interaction not resolved\", \"Whether HCFC2 dependency is universal for all IRF2 targets unknown\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Convergent forward genetic and CRISPR screens established IRF2 as a direct transcriptional activator of GSDMD and CASP4, two essential executors of pyroptosis, and of MHC-I pathway components (immunoproteasomes, TAP, ERAP1), while simultaneously repressing PD-L1 and CXCL3, placing IRF2 at a regulatory nexus of innate immunity, antigen presentation, and tumor immune evasion.\",\n      \"evidence\": \"ENU screen and ChIP/mutagenesis for GSDMD; CRISPR screen in human monocytes for CASP4; CRISPR screen in HeLa for MHC-I pathway; KRAS-driven CRC models for CXCL3 axis\",\n      \"pmids\": [\"31113851\", \"31353801\", \"31471524\", \"30905761\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether GSDMD and CASP4 activation uses the latent activation domain or a distinct mechanism not resolved\", \"Direct binding to CASP4 promoter not confirmed by ChIP\", \"Quantitative contribution of IRF2 loss to immune evasion in patients not established\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Tissue-specific conditional deletion showed that IRF2 maintains colonic stem cell self-renewal by limiting IFN signaling, with its loss causing premature differentiation and impaired epithelial regeneration after colitis, extending IRF2's IFN-attenuating role to epithelial homeostasis.\",\n      \"evidence\": \"Irf2ΔIEC conditional KO mice with organoid assays, flow cytometry, poly(I:C) and DSS colitis models\",\n      \"pmids\": [\"32901054\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct IRF2 target genes in colonic stem cells not identified\", \"Whether type I vs. type III IFN is the dominant signal restrained by IRF2 in gut epithelium not distinguished\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Cell-type-specific deletion of IRF2 in CD8+ T cells prevented acquisition of the exhaustion transcriptional program in tumors and sustained effector function, establishing that IFN-driven IRF2 expression is a critical checkpoint linking chronic IFN signaling to T cell dysfunction.\",\n      \"evidence\": \"CD8+ T cell-specific IRF2 conditional KO, adoptive transfer into tumor-bearing mice, transcriptional profiling, checkpoint blockade experiments\",\n      \"pmids\": [\"36370712\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct transcriptional targets of IRF2 that execute the exhaustion program in CD8+ T cells not catalogued\", \"Whether IRF2 acts alone or requires co-factors (e.g. TOX, NFAT) for exhaustion programming unknown\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Placement of IRF2 downstream of NOTCH2 signaling in the Ly6Chi-to-Ly6Clo nonclassical monocyte transition resolved the signaling hierarchy controlling this differentiation step and established IRF2 as the required transcription factor independently of NUR77 and BCL6.\",\n      \"evidence\": \"IRF2 KO mice, myeloid progenitor-specific deletions, in vitro DLL1-induced transition assay with flow cytometry\",\n      \"pmids\": [\"37607223\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct IRF2 target genes that execute the nonclassical monocyte program not identified\", \"Whether NOTCH2 directly induces IRF2 expression or acts through intermediaries not resolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Major open questions include the identity of the full genome-wide IRF2 target repertoire in specific cell types, the structural basis for context-dependent switching between repressor and activator modes, the interplay among phosphorylation/SUMOylation/ubiquitination in regulating IRF2 function in vivo, and the therapeutic potential of modulating IRF2 to reverse CD8+ T cell exhaustion in cancer immunotherapy.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No full-length IRF2 structure in complex with corepressors or coactivators\", \"In vivo phosphosite-specific mutant phenotypes not characterized\", \"Pharmacological tools to modulate IRF2 activity do not exist\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [0, 1, 5, 9, 15, 24]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 3, 5, 8, 10, 14, 24, 25, 26]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [3, 9, 17]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0098542\", \"supporting_discovery_ids\": []},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 3, 5, 8, 10, 14, 24, 25, 26]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [2, 11, 19, 25, 26, 32]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [5, 8]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [24, 25, 30]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"IRF1\", \"PIASy\", \"MDM2\", \"RELA\", \"HCFC2\", \"BLIMP1\"],\n    \"other_free_text\": []\n  }\n}\n```"}